mk-3655
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2016 (NCT02708576)
Timeline
Indications
Mechanism of action
- Fibroblast growth factor receptor 1INHIBITOR
FGFR1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- ngm313
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04583423 | Phase 2 | Nov 11, 2020 | Merck |
| NCT03298464 | Phase 1 | Sep 11, 2017 | NGM Biopharmaceuticals, Inc |
| NCT02708576 | Phase 1 | Feb 1, 2016 | NGM Biopharmaceuticals, Inc |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NGM Biopharmaceuticals, Inc | For profit | 2 | 2 | 1 | 2016 |
| Merck | For profit | 1 | 1 | 1 | 2020 |
2 organizations
Page 1 / 1